Dissemin is shutting down on January 1st, 2025

Published in

Massachusetts Medical Society, New England Journal of Medicine, 19(372), p. 1791-1800

DOI: 10.1056/nejmoa1500857

Yearbook of Cardiology 2016, p. 24-26

DOI: 10.5005/jp/books/12834_8

Links

Tools

Export citation

Search in Google Scholar

Long-term use of ticagrelor in patients with prior myocardial infarction.

Journal article published in 2015 by W. van Gaal, P. van de Borne, L. dos Santos, J. de Souza, A. de Paiva, F. dos Santos, A. de Lorenzo, J. vom Dahl, E. C. de Melker, A. van der Spoel, A. van der Sluis, F. R. den Hartog, C. van Daalen, R. J. M. de Vries, M. E. R. M. van Daele and other authors.
This paper is available in a repository.
This paper is available in a repository.

Full text: Download

Green circle
Preprint: archiving allowed
Green circle
Postprint: archiving allowed
Orange circle
Published version: archiving restricted
Data provided by SHERPA/RoMEO

Abstract

To the Editor: In their report on the PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients with Prior Heart Attack using Ticagrelor Compared to Placebo on the Background of Aspirin-Thrombolysis in Myocardial Infarction 54) trial, Bonaca et al. (May 7 issue)(1) suggest that the benefit of dual antiplatelet therapy comes at a cost of an increased risk of bleeding events. A dual antiplatelet regimen administered at an even lower dose than the one used in this study could confer a reduced risk of bleeding events and improved secondary prophylaxis against recurrent ischemic events as compared with aspirin. We successfully tested . . .